IDEAS home Printed from https://ideas.repec.org/r/nbr/nberwo/10536.html
   My bibliography  Save this item

Mergers and Acquisitions in the Pharmaceutical and Biotech Industries

Citations

Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
as


Cited by:

  1. Manuel Hermosilla, 2021. "Rushed Innovation: Evidence from Drug Licensing," Management Science, INFORMS, vol. 67(1), pages 257-278, January.
  2. Walter Park & Ralph Sonenshine, 2012. "Impact of Horizontal Mergers on Research & Development and Patenting: Evidence from Merger Challenges in the U.S," Journal of Industry, Competition and Trade, Springer, vol. 12(1), pages 143-167, March.
  3. Raymond J. Fisman & Rakesh Khurana & Matthew Rhodes-Kropf & Soojin Yim, 2014. "Governance and CEO Turnover: Do Something or Do the Right Thing?," Management Science, INFORMS, vol. 60(2), pages 319-337, February.
  4. Christos Genakos & Andreas Lamprinidis & James Walker, 2023. "Evaluating merger effects," CEP Discussion Papers dp1921, Centre for Economic Performance, LSE.
  5. Abhirup Chakrabarti, 2015. "Organizational adaptation in an economic shock: The role of growth reconfiguration," Strategic Management Journal, Wiley Blackwell, vol. 36(11), pages 1717-1738, November.
  6. Yoonje Euh & Daeho Lee, 2021. "How Do Pharmaceutical Companies Overcome a Corporate Productivity Crisis? Business Diversification into Medical Devices for Growth Potential," IJERPH, MDPI, vol. 18(3), pages 1-10, January.
  7. Hsu, Po-Hsuan & Huang, Peng & Humphery-Jenner, Mark & Powell, Ronan, 2021. "Cross-border mergers and acquisitions for innovation," Journal of International Money and Finance, Elsevier, vol. 112(C).
  8. Ye Jin Lee & Kwangsoo Shin & Eungdo Kim, 2019. "The Influence of a Firm’s Capability and Dyadic Relationship of the Knowledge Base on Ambidextrous Innovation in Biopharmaceutical M&As," Sustainability, MDPI, vol. 11(18), pages 1-17, September.
  9. Qiao, Lu & Dong, Weijia & Lv, Xin, 2023. "The heterogeneous impacts of M&As on renewable energy firms’ innovation: Comparative analysis of China, the US and EU," International Review of Economics & Finance, Elsevier, vol. 87(C), pages 306-323.
  10. Diana Marieta Mihaiu & Radu-Alexandru Șerban & Alin Opreana & Mihai Țichindelean & Vasile Brătian & Liliana Barbu, 2021. "The Impact of Mergers and Acquisitions and Sustainability on Company Performance in the Pharmaceutical Sector," Sustainability, MDPI, vol. 13(12), pages 1-24, June.
  11. Tjandrawinata, Raymond R. & Simanjuntak, Destrina Grace, 2012. "Factors affecting productivity of research-based pharmaceutical companies following mergers and acquisitions," MPRA Paper 42514, University Library of Munich, Germany.
  12. Basant, Rakesh & Jaiswal, Neha, 2022. "Impact of Mergers and Acquisitions on Innovation: Evidence from a Panel of Indian Pharmaceutical Firms," IIMA Working Papers WP 2022-01-01, Indian Institute of Management Ahmedabad, Research and Publication Department.
  13. Barbara Fidanza, 2017. "Quali driver nella selezione delle target in operazioni di M&A? Una verifica empirica nel mercato italiano," Working Papers 52-2017, Macerata University, Department of Studies on Economic Development (DiSSE), revised Jan 2018.
  14. Valérie Revest & Alessandro Sapio, 2016. "Graduation and sell-out strategies in the Alternative Investment Market," Discussion Papers 4_2016, CRISEI, University of Naples "Parthenope", Italy.
  15. Andersson, Martin & Xiao, Jing, 2016. "Acquisitions of start-ups by incumbent businesses," Research Policy, Elsevier, vol. 45(1), pages 272-290.
  16. Lars Calmfors & Giancarlo Corsetti & Seppo Honkapohja & Gilles Saint-Paul & Hans-Werner Sinn & John Kay & Jan-Egbert Sturm & Xavier Vives, 2006. "Chapter 5: Mergers and Competition Policy in Europe," EEAG Report on the European Economy, CESifo, vol. 0, pages 101-116, March.
  17. Lee, Donghyun, 2017. "Cross-border mergers and acquisitions with heterogeneous firms: Technology vs. market motives," The North American Journal of Economics and Finance, Elsevier, vol. 42(C), pages 20-37.
  18. Santosh K. Sahu & Nitika Agarwal, 2015. "Mergers and Acquisitions in the Indian Pharmaceutical Sector," Working Papers 2015-122, Madras School of Economics,Chennai,India.
  19. Andersson, Martin & Xiao, Jing, 2014. "Acquisitions of Start-ups by Incumbent Businesses A market selection process of “high-quality” entrants?," Papers in Innovation Studies 2014/19, Lund University, CIRCLE - Centre for Innovation Research.
  20. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
  21. Christos Genakos & Andreas Lamprinidis & James Walker, 2023. "Evaluating merger effects," POID Working Papers 072, Centre for Economic Performance, LSE.
  22. Thomas Canace & Steven Mann, 2014. "The impact of technology-motivated M&A and joint ventures on the value of IT and non-IT firms: a new examination," Review of Quantitative Finance and Accounting, Springer, vol. 43(2), pages 333-366, August.
  23. Desyllas, Panos & Hughes, Alan, 2010. "Do high technology acquirers become more innovative?," Research Policy, Elsevier, vol. 39(8), pages 1105-1121, October.
  24. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
  25. Luca Verginer & Federica Parisi & Jeroen van Lidth de Jeude & Massimo Riccaboni, 2022. "The Impact of Acquisitions in the Biotechnology Sector on R&D Productivity," Papers 2203.12968, arXiv.org, revised Jan 2024.
  26. Barrenho, E & Smith, PC & Miraldo, M, 2013. "The determinants of attrition in drug development: a duration analysis," Working Papers 12204, Imperial College, London, Imperial College Business School.
  27. Abhirup Chakrabarti & Will Mitchell, 2016. "The role of geographic distance in completing related acquisitions: Evidence from U.S. chemical manufacturers," Strategic Management Journal, Wiley Blackwell, vol. 37(4), pages 673-694, April.
  28. Ornaghi, Carmine, 2009. "Mergers and innovation in big pharma," International Journal of Industrial Organization, Elsevier, vol. 27(1), pages 70-79, January.
  29. Mariana Mazzucato & Stuart Parris, 2015. "High-growth firms in changing competitive environments: the US pharmaceutical industry (1963 to 2002)," Small Business Economics, Springer, vol. 44(1), pages 145-170, January.
  30. Sorisio, Enrico & Strøm, Steinar, 2006. "Innovation and market dynamics in the EPO market," Memorandum 12/2006, Oslo University, Department of Economics.
  31. Elisa Barbieri & Manli Huang & Shenglei Pi & Mattia Tassinari, 2017. "Restructuring the Production of Medicines: An Investigation on the Pharmaceutical Sector in China and the Role of Mergers and Acquisitions," IJERPH, MDPI, vol. 14(10), pages 1-21, October.
  32. Yasin Ç?LHOROZ & Cuma SON?UR & Mehmet GÖZLÜ & Murat KONCA, 2016. "Mergers And Acquisit?ons In Pharmaceutical Industry As A Growth Strategy: An Investigation Upon Practice," International Journal of Business and Management, International Institute of Social and Economic Sciences, vol. 4(3), pages 1-12, August.
  33. Akdoğu, Evrim & Simsir, Serif Aziz, 2023. "Are blockchain and cryptocurrency M&As harder to close?," Finance Research Letters, Elsevier, vol. 52(C).
  34. Ute Laermann-Nguyen & Martin Backfisch, 2021. "Innovation crisis in the pharmaceutical industry? A survey," SN Business & Economics, Springer, vol. 1(12), pages 1-37, December.
  35. Saud Althaqeb, 2017. "Survey of Energy Finance on the Corporate World," International Journal of Energy Economics and Policy, Econjournals, vol. 7(6), pages 153-158.
  36. Higgins, Matthew J. & Rodriguez, Daniel, 2006. "The outsourcing of R&D through acquisitions in the pharmaceutical industry," Journal of Financial Economics, Elsevier, vol. 80(2), pages 351-383, May.
  37. Burçak Polat, 2017. "FDI entry mode choice and ownership structure in Turkish market: A firm-level analysis," Cogent Economics & Finance, Taylor & Francis Journals, vol. 5(1), pages 1283762-128, January.
  38. Maé Geymond, 2020. "The influence of local institutional and historical frameworks on a globalized industry: The case of the pharmaceutical industry in France and Quebec," Post-Print halshs-02900915, HAL.
  39. Ornaghi, Carmine, 2006. "Mergers and innovation: the case of the pharmaceutical industry," Discussion Paper Series In Economics And Econometrics 0605, Economics Division, School of Social Sciences, University of Southampton.
  40. Jan Malek & Melissa Newham & Jo Seldeslachts & Reinhilde Veugelers, 2024. "Acquiring R&D projects: who, when, and what? Evidence from antidiabetic drug development," Working Papers of Department of Management, Strategy and Innovation, Leuven 735739, KU Leuven, Faculty of Economics and Business (FEB), Department of Management, Strategy and Innovation, Leuven.
  41. Christopher Paul Adams & Van Vu Brantner, 2010. "Spending on new drug development," Health Economics, John Wiley & Sons, Ltd., vol. 19(2), pages 130-141, February.
  42. Joshua L. Krieger & Xuelin Li & Richard T. Thakor, 2022. "Find and Replace: R&D Investment Following the Erosion of Existing Products," Management Science, INFORMS, vol. 68(9), pages 6552-6571, September.
  43. Lo Nigro, Giovanna & Perrone, Giovanni & Chiapparrone, Silvia, 2012. "Governance forms drivers in bio-pharmaceutical inter-firm relationships," International Journal of Production Economics, Elsevier, vol. 140(2), pages 604-613.
  44. Michaël Dewally & Susan M.V. Flaherty & Yingying Shao, 2017. "Determinants of financial policy in the hospitality sector in the United States," Tourism Economics, , vol. 23(3), pages 523-542, May.
  45. Marco Ceccagnoli & Matthew J. Higgins & Vincenzo Palermo, 2014. "Behind the Scenes: Sources of Complementarity in R&D," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 23(1), pages 125-148, March.
  46. Shansong Huang & Yang Bai & Qingmei Tan, 2017. "How Does the Concentration of Determinants Affect Industrial Innovation Performance? – An Empirical Analysis of 23 Chinese Industrial Sectors," PLOS ONE, Public Library of Science, vol. 12(1), pages 1-15, January.
  47. Pyykkö, Elina, 2009. "Stock market valuation of R&D spending of firms acquiring targets from technologically abundant countries," Journal of Multinational Financial Management, Elsevier, vol. 19(2), pages 111-126, April.
  48. Nishimura, Junichi & Okada, Yosuke, 2014. "R&D portfolios and pharmaceutical licensing," Research Policy, Elsevier, vol. 43(7), pages 1250-1263.
  49. Ozmel, Umit & Robinson, David T. & Stuart, Toby E., 2013. "Strategic alliances, venture capital, and exit decisions in early stage high-tech firms," Journal of Financial Economics, Elsevier, vol. 107(3), pages 655-670.
  50. Abhirup Chakrabarti & Will Mitchell, 2013. "The Persistent Effect of Geographic Distance in Acquisition Target Selection," Organization Science, INFORMS, vol. 24(6), pages 1805-1826, December.
  51. K D S Fernald & H P G Pennings & J F van den Bosch & H R Commandeur & E Claassen, 2017. "The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-22, February.
  52. Genakos, Christos & Lamprinidis, Andreas & Walker, James, 2023. "Evaluating merger effects," LSE Research Online Documents on Economics 121325, London School of Economics and Political Science, LSE Library.
  53. Tannista Banerjee & Arnab Nayak, 2015. "Comparing Domestic and Cross-Border Mergers and Acquisitions in the Pharmaceutical Industry," Atlantic Economic Journal, Springer;International Atlantic Economic Society, vol. 43(4), pages 489-499, December.
  54. Panos Desyllas, 2009. "Improving performance through vertical disintegration: evidence from UK manufacturing firms," Managerial and Decision Economics, John Wiley & Sons, Ltd., vol. 30(5), pages 307-324.
  55. McCarthy, Killian J. & Aalbers, Hendrik Leendert, 2016. "Technological acquisitions: The impact of geography on post-acquisition innovative performance," Research Policy, Elsevier, vol. 45(9), pages 1818-1832.
  56. Haucap, Justus & Rasch, Alexander & Stiebale, Joel, 2019. "How mergers affect innovation: Theory and evidence," International Journal of Industrial Organization, Elsevier, vol. 63(C), pages 283-325.
  57. Karen Ruckman & Ian McCarthy, 2017. "Why do some patents get licensed while others do not?," Industrial and Corporate Change, Oxford University Press and the Associazione ICC, vol. 26(4), pages 667-688.
  58. Jinhee Kwon & Cheong Kim & Kun Chang Lee, 2020. "Moderating Effect of the Continental Factor on the Business Strategy and M&A Performance in the Pharmaceutical Industry for Sustainable International Business," Sustainability, MDPI, vol. 12(12), pages 1-14, June.
  59. Mahdiyeh Entezarkheir & Saeed Moshiri, 2019. "Is innovation a factor in merger decisions? Evidence from a panel of US firms," Empirical Economics, Springer, vol. 57(5), pages 1783-1809, November.
  60. Yasin Ç?LHOROZ & Cuma SON?UR & Mehmet GÖZLÜ & Murat KONCA, 2016. "Mergers And Acquisit?ons In Pharmaceutical Industry As A Growth Strategy: An Investigation Upon Practice," Proceedings of International Academic Conferences 4006562, International Institute of Social and Economic Sciences.
  61. Bennato, Anna Rita & Davies, Stephen & Mariuzzo, Franco & Ormosi, Peter, 2021. "Mergers and innovation: Evidence from the hard disk drive market," International Journal of Industrial Organization, Elsevier, vol. 77(C).
  62. Suin Lee & Christos Pantzalis & Jung Chul Park, 2024. "Interstate migration‐based social networks and M&A decisions," The Financial Review, Eastern Finance Association, vol. 59(1), pages 113-153, February.
  63. Anna Rita Bennato & Stephen Davies & Franco Mariuzzo & Peter Ormosi, 2019. "Mergers and Innovation: Evidence from the Hard Disk Drive Market," Working Paper series, University of East Anglia, Centre for Competition Policy (CCP) 2018-04v3, Centre for Competition Policy, University of East Anglia, Norwich, UK..
  64. Juha‐Pekka Kallunki & Elina Pyykkö & Tomi Laamanen, 2009. "Stock Market Valuation, Profitability and R&D Spending of the Firm: The Effect of Technology Mergers and Acquisitions," Journal of Business Finance & Accounting, Wiley Blackwell, vol. 36(7‐8), pages 838-862, September.
  65. Mahdiyeh Entezarkheir & Saeed Moshiri, 2021. "Innovation spillover and merger decisions," Empirical Economics, Springer, vol. 61(5), pages 2419-2448, November.
  66. Panayotis Dessyllas & Alan Hughes, 2005. "The Revealed Preferences of High Technology Acquirers: An Analysis of the Characteristics of their Targets," Industrial Organization 0507009, University Library of Munich, Germany.
  67. Schön, Benjamin & Pyka, Andreas, 2013. "The success factors of technology-sourcing through mergers & acquisitions: An intuitive meta-analysis," FZID Discussion Papers 78-2013, University of Hohenheim, Center for Research on Innovation and Services (FZID).
  68. Silvina A. Romano & Jon Mikel Zabala‐Iturriagagoitia, 2022. "Davids versus Goliaths: Epigenetic dynamics and structural change in the Swedish innovation system," Growth and Change, Wiley Blackwell, vol. 53(4), pages 1737-1761, December.
  69. Ralph Siebert & Zhili Tian, 2020. "Dynamic Mergers Effects on R&D Investments and Drug Development across Research Phases in the Pharmaceutical Industry," CESifo Working Paper Series 8303, CESifo.
  70. Magazzini Laura & Fabio Pammolli & Massimo Riccaboni, 2013. "R&D, Within and Between Patent Competition in the Pharmaceutical Industry," Working Papers 3/2013, IMT School for Advanced Studies Lucca, revised Jul 2013.
  71. Bertrand, Olivier, 2009. "Effects of foreign acquisitions on R&D activity: Evidence from firm-level data for France," Research Policy, Elsevier, vol. 38(6), pages 1021-1031, July.
  72. Felipa de Mello-Sampayo & Sofia de Sousa-Vale & Francisco Camoes, 2015. "Substitutability Between Drugs, Innovation, and Fiscal Policy in the Pharmaceutical Industry," Annals of Economics and Finance, Society for AEF, vol. 16(2), pages 273-289, November.
  73. Williams, David R., 2013. "Human and financial capital as determinants of biopharmaceutical IPO de-listings," Journal of Business Research, Elsevier, vol. 66(12), pages 2612-2618.
IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.